Loading...

bioMérieux

ENXTPA:BIM
Snowflake Description

Flawless balance sheet with acceptable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BIM
ENXTPA
€9B
Market Cap
Add to portfolio
  1. Home
    2. ›
  2. FR
    3. ›
  3. Healthcare
Last updated 2019/06/17 20:33
Company description

bioMérieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The last earnings update was 94 days ago. More info.

Find similar companies

Add to Portfolio Compare Print
BIM Share Price and Events
7 Day Returns
3.3%
ENXTPA:BIM
0.2%
FR Medical Equipment
-0.1%
FR Market
1 Year Returns
-3%
ENXTPA:BIM
-14.5%
FR Medical Equipment
-2.5%
FR Market
BIM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
bioMérieux (BIM) 3.3% 4% 3.4% -3% 101.7% 186%
FR Medical Equipment 0.2% 0.5% 0.2% -14.5% 48.9% 56%
FR Market -0.1% -1.3% -0.3% -2.5% 34% 27.3%
1 Year Return vs Industry and Market
  • BIM outperformed the Medical Equipment industry which returned -14.5% over the past year.
Price Volatility
BIM
Industry
5yr Volatility vs Market

BIM Value

 Is bioMérieux undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of bioMérieux to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for bioMérieux.

ENXTPA:BIM Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 12 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.9%
Perpetual Growth Rate 10-Year FR Government Bond Rate 0.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ENXTPA:BIM
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year FR Govt Bond Rate 0.7%
Equity Risk Premium S&P Global 6.7%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.85
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.852 (1 + (1- 33%) (6.06%)) 		0.924
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)		 0.92
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.73% + (0.924 * 6.65%) 		6.88%

Discounted Cash Flow Calculation for ENXTPA:BIM using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for bioMérieux is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

ENXTPA:BIM DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 6.88%)
2019 198.29 Analyst x8 185.53
2020 236.83 Analyst x8 207.33
2021 264.58 Analyst x5 216.73
2022 292.00 Analyst x2 223.81
2023 331.50 Analyst x2 237.74
2024 357.94 Est @ 7.98% 240.19
2025 378.72 Est @ 5.8% 237.78
2026 394.94 Est @ 4.28% 232.01
2027 407.65 Est @ 3.22% 224.07
2028 417.73 Est @ 2.47% 214.84
Present value of next 10 years cash flows €2,220.03
ENXTPA:BIM DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €417.73 × (1 + 0.73%) ÷ (6.88% – 0.73%) 		€6,850.53
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €6,850.53 ÷ (1 + 6.88%)10 		€3,523.27
ENXTPA:BIM Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €2,220.03 + €3,523.27 		€5,743.30
Equity Value per Share
(EUR)		 = Total value / Shares Outstanding
= €5,743.30 / 117.80 		€48.75
ENXTPA:BIM Discount to Share Price
Calculation Result
Value per share (EUR) From above. €48.75
Current discount Discount to share price of €76.65
= -1 x (€76.65 - €48.75) / €48.75 		-57.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of bioMérieux is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for bioMérieux's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are bioMérieux's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ENXTPA:BIM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €2.18
ENXTPA:BIM Share Price ** ENXTPA (2019-06-17) in EUR €76.65
Europe Medical Equipment Industry PE Ratio Median Figure of 55 Publicly-Listed Medical Equipment Companies 32.84x
France Market PE Ratio Median Figure of 423 Publicly-Listed Companies 17.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of bioMérieux.

ENXTPA:BIM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:BIM Share Price ÷ EPS (both in EUR)

= 76.65 ÷ 2.18

 35.16x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • bioMérieux is overvalued based on earnings compared to the Europe Medical Equipment industry average.
  • bioMérieux is overvalued based on earnings compared to the France market.
Price based on expected Growth
Does bioMérieux's expected growth come at a high price?
Raw Data
ENXTPA:BIM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 35.16x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts		 10.5%per year
Europe Medical Equipment Industry PEG Ratio Median Figure of 39 Publicly-Listed Medical Equipment Companies 2.36x
France Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.52x

*Line of best fit is calculated by linear regression .

ENXTPA:BIM PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 35.16x ÷ 10.5%

 3.36x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • bioMérieux is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on bioMérieux's assets?
Raw Data
ENXTPA:BIM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €16.38
ENXTPA:BIM Share Price * ENXTPA (2019-06-17) in EUR €76.65
France Medical Equipment Industry PB Ratio Median Figure of 27 Publicly-Listed Medical Equipment Companies 1.89x
France Market PB Ratio Median Figure of 623 Publicly-Listed Companies 1.46x
ENXTPA:BIM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:BIM Share Price ÷ Book Value per Share (both in EUR)

= 76.65 ÷ 16.38

 4.68x

* Primary Listing of bioMérieux.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • bioMérieux is overvalued based on assets compared to the FR Medical Equipment industry average.
X
Value checks
We assess bioMérieux's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
    5. bioMérieux has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

BIM Future Performance

 How is bioMérieux expected to perform in the next 1 to 3 years based on estimates from 12 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
10.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is bioMérieux expected to grow at an attractive rate?
  • bioMérieux's earnings growth is expected to exceed the low risk savings rate of 0.7%.
Growth vs Market Checks
  • bioMérieux's earnings growth is positive but not above the France market average.
  • bioMérieux's revenue growth is expected to exceed the France market average.
Annual Growth Rates Comparison
Raw Data
ENXTPA:BIM Future Growth Rates Data Sources
Data Point Source Value (per year)
ENXTPA:BIM Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts 10.5%
ENXTPA:BIM Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 12 Analysts 7%
France Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13.1%
France Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 9.6%
France Market Earnings Growth Rate Market Cap Weighted Average 12.8%
France Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ENXTPA:BIM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ENXTPA:BIM Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 3,487 606 464 1
2022-12-31 3,304 586 415 2
2021-12-31 3,017 519 349 6
2020-12-31 2,805 488 309 12
2019-12-31 2,625 438 278 11
ENXTPA:BIM Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 2,421 387 257
2018-09-30 2,372 363 264
2018-06-30 2,323 355 271
2018-03-31 2,306 356 255
2017-12-31 2,288 341 238
2017-09-30 2,262 340 216
2017-06-30 2,237 339 195
2017-03-31 2,170 337 187
2016-12-31 2,103 336 179
2016-09-30 2,068 339 158
2016-06-30 2,032 342 137
2016-03-31 1,998 326 124

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • bioMérieux's earnings are expected to grow by 10.5% yearly, however this is not considered high growth (20% yearly).
  • bioMérieux's revenue is expected to grow by 7% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ENXTPA:BIM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below

All data from bioMérieux Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:BIM Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 3.92 3.92 3.92 1.00
2022-12-31 3.54 3.54 3.54 1.00
2021-12-31 2.91 3.17 2.82 5.00
2020-12-31 2.62 2.73 2.51 8.00
2019-12-31 2.34 2.42 2.23 8.00
ENXTPA:BIM Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 2.18
2018-09-30 2.24
2018-06-30 2.30
2018-03-31 2.16
2017-12-31 2.02
2017-09-30 1.83
2017-06-30 1.65
2017-03-31 1.58
2016-12-31 1.51
2016-09-30 1.33
2016-06-30 1.15
2016-03-31 1.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • bioMérieux is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess bioMérieux's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the France market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the France market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
bioMérieux has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

BIM Past Performance

  How has bioMérieux performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare bioMérieux's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • bioMérieux's year on year earnings growth rate has been positive over the past 5 years.
  • bioMérieux's 1-year earnings growth is less than its 5-year average (7.8% vs 15.9%)
  • bioMérieux's earnings growth has not exceeded the Europe Medical Equipment industry average in the past year (7.8% vs 9%).
Earnings and Revenue History
bioMérieux's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from bioMérieux Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:BIM Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 2,421.30 256.60 645.50 326.90
2018-09-30 2,372.20 264.00 627.90 319.50
2018-06-30 2,323.10 271.40 610.30 312.10
2018-03-31 2,305.65 254.75 607.10 308.25
2017-12-31 2,288.20 238.10 603.90 304.40
2017-09-30 2,262.45 216.30 603.90 299.65
2017-06-30 2,236.70 194.50 603.90 294.90
2017-03-31 2,169.95 186.80 586.70 283.40
2016-12-31 2,103.20 179.10 569.50 271.90
2016-09-30 2,067.70 157.85 554.60 260.20
2016-06-30 2,032.20 136.60 539.70 248.50
2016-03-31 1,998.40 123.55 534.45 243.70
2015-12-31 1,964.60 110.50 529.20 238.90
2015-09-30 1,907.75 127.30 510.35 230.40
2015-06-30 1,850.90 144.10 491.50 221.90
2015-03-31 1,774.65 139.50 472.25 213.85
2014-12-31 1,698.40 134.90 453.00 205.80
2014-09-30 1,656.40 134.95 437.45 200.95
2014-06-30 1,614.40 135.00 421.90 196.10
2014-03-31 1,601.15 149.65 413.25 190.95
2013-12-31 1,587.90 164.30 404.60 185.80
2013-09-30 1,580.75 149.65 407.05 184.30
2013-06-30 1,573.60 135.00 409.50 181.60
2013-03-31 1,571.70 134.70 409.25 176.30
2012-12-31 1,569.80 134.40 409.00 171.00
2012-09-30 1,537.00 148.80 398.40 163.95
2012-06-30 1,504.20 163.20 387.80 159.20

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • bioMérieux has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • bioMérieux used its assets more efficiently than the Europe Medical Equipment industry average last year based on Return on Assets.
  • bioMérieux has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess bioMérieux's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
bioMérieux has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

BIM Health

 How is bioMérieux's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up bioMérieux's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • bioMérieux is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • bioMérieux's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of bioMérieux's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from bioMérieux Company Filings, last reported 5 months ago.

ENXTPA:BIM Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 2,003.30 547.00 280.10
2018-09-30 2,003.30 547.00 280.10
2018-06-30 1,838.60 455.40 194.30
2018-03-31 1,838.60 455.40 194.30
2017-12-31 1,736.70 468.00 312.10
2017-09-30 1,736.70 468.00 312.10
2017-06-30 1,639.70 462.50 182.20
2017-03-31 1,639.70 462.50 182.20
2016-12-31 1,621.30 453.30 178.60
2016-09-30 1,621.30 453.30 178.60
2016-06-30 1,510.00 391.80 126.30
2016-03-31 1,510.00 391.80 126.30
2015-12-31 1,502.60 370.70 147.10
2015-09-30 1,502.60 370.70 147.10
2015-06-30 1,441.60 385.50 108.90
2015-03-31 1,441.60 385.50 108.90
2014-12-31 1,388.70 369.20 119.70
2014-09-30 1,388.70 369.20 119.70
2014-06-30 1,273.20 403.30 95.10
2014-03-31 1,273.20 403.30 95.10
2013-12-31 1,267.30 403.10 428.00
2013-09-30 1,267.30 403.10 428.00
2013-06-30 1,205.00 101.30 58.50
2013-03-31 1,205.00 101.30 58.50
2012-12-31 1,160.20 114.00 65.60
2012-09-30 1,200.30 114.00 65.60
2012-06-30 1,157.80 179.40 85.60
  • bioMérieux's level of debt (27.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (31.8% vs 27.3% today).
  • Debt is well covered by operating cash flow (70.7%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 23x coverage).
Show me more healthy companies in the Medical Equipment industry
X
Financial health checks
We assess bioMérieux's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
    7. bioMérieux has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

BIM Dividends

 What is bioMérieux's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.46%
Current annual income from bioMérieux dividends. Estimated to be 0.62% next year.
If you bought €2,000 of bioMérieux shares you are expected to receive €9 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • bioMérieux's pays a lower dividend yield than the bottom 25% of dividend payers in France (1.54%).
  • bioMérieux's dividend is below the markets top 25% of dividend payers in France (4.41%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ENXTPA:BIM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
Europe Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 40 Stocks 1.5%
France Market Average Dividend Yield Market Cap Weighted Average of 322 Stocks 3.1%
France Minimum Threshold Dividend Yield 10th Percentile 0.9%
France Bottom 25% Dividend Yield 25th Percentile 1.5%
France Top 25% Dividend Yield 75th Percentile 4.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ENXTPA:BIM Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31 0.73 1.00
2022-12-31 0.66 2.00
2021-12-31 0.49 7.00
2020-12-31 0.47 10.00
2019-12-31 0.40 9.00
ENXTPA:BIM Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2019-03-15 0.350 0.476
2019-02-27 0.350 0.479
2018-03-15 0.340 0.500
2018-02-28 0.340 0.524
2017-03-15 0.333 0.510
2017-03-01 0.333 0.690
2016-03-17 0.333 0.788
2016-03-02 0.333 0.997
2015-04-28 0.333 0.968
2015-03-11 0.333 1.081
2014-04-29 0.333 1.196
2014-03-19 0.333 1.280
2013-04-15 0.327 1.310
2013-03-13 0.327 1.346
2012-03-13 0.327 1.446
2011-04-08 0.327 1.459
2011-03-08 0.327 1.318
2010-03-08 0.307 1.165

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • bioMérieux is not paying a notable dividend for France, therefore no need to check if the payments are stable.
  • bioMérieux is not paying a notable dividend for France, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of bioMérieux's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of bioMérieux's dividends as it is not paying a notable one for France.
Future Payout to shareholders
  • No need to calculate the sustainability of bioMérieux's dividends in 3 years as they are not expected to pay a notable one for France.
X
Income/ dividend checks
We assess bioMérieux's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can bioMérieux afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
    7. bioMérieux has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

BIM Management

 What is the CEO of bioMérieux's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Alexandre Mérieux
COMPENSATION €1,360,165
AGE 44
TENURE AS CEO 1.5 years
CEO Bio

Mr. Alexandre Mérieux serves as the Chairman and Chief Executive Officer of bioMérieux, Inc. Mr. Mérieux serves as the President and Chairman of the Management Board of Merieux Développement SAS. He joined the firm in 2009 and serves as its President from 2009. Mr. Mérieux serves as Director of Compagnie Plastic Omnium SA since April 26, 2018. He joined the Industrial Microbiology Division of bioMérieux in 2005 where he served as a Corporate Vice President. Mr. Mérieux served as a Deputy Chief Executive Officer and Corporate Vice-President of Microbiology Unit & Manufacturing & Supply Operations at bioMérieux, Inc. He serves as the Chief Operating Officer and Corporate Vice President of Microbiology Unit at bioMérieux SA and served as its Corporate Vice President of Industrial Microbiology Division, Managing Director, Deputy Managing Director and Director Général Délégué. He served as Vice President of Institut MÃrieux SA. From 1999 to 2004, Mr. Mérieux worked for the Silliker Group Corporation, working in marketing in the U.S. and Europe and as a Marketing and Business Unit Director in France. He is a Board Member of Ceva Sante Animale S.A. since September 2013; he has chaired the Board of Merieux NutriSciences. Mr. Mérieux holds a degree in Biology from Lyon I University and is a graduate of HEC Montreal Business School.

CEO Compensation
  • Alexandre's compensation has increased by more than 20% in the past year whilst earnings grew less than 20%.
  • Alexandre's remuneration is lower than average for companies of similar size in France.
Management Team Tenure

Average tenure and age of the bioMérieux management team in years:

1.3
Average Tenure
44
Average Age
  • The average tenure for the bioMérieux management team is less than 2 years, this suggests a new team.
Management Team

Alexandre Mérieux

TITLE
Chairman & CEO
COMPENSATION
€1M
AGE
44
TENURE
1.5 yrs

Guillaume Bouhours

TITLE
Executive VP and Executive VP of Finance
AGE
42
TENURE
1.3 yrs

Sylvain Morgeau

TITLE
Investor Relations

Valérie Leyldé

TITLE
Executive VP of Human Resources and Communications
TENURE
0.4 yrs

Michel Baguenault

TITLE
Executive VP & Company Secretary
TENURE
0.4 yrs

François Lacoste

TITLE
Executive Vice President of Clinical Unit
TENURE
1.3 yrs

Stefan Willemsen

TITLE
Executive Vice President of Americas Region
TENURE
1.3 yrs

Mark Miller

TITLE
Executive VP & Chief Medical Officer
TENURE
6.7 yrs

Nicolas Cartier

TITLE
Executive Vice President of Industrial microbiology Unit
AGE
51
TENURE
1.3 yrs

Pierre Charbonnier

TITLE
Executive Vice President of Global Quality
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the bioMérieux board of directors in years:

3.6
Average Tenure
60.5
Average Age
  • The tenure for the bioMérieux board of directors is about average.
Board of Directors

Alexandre Mérieux

TITLE
Chairman & CEO
COMPENSATION
€1M
AGE
44
TENURE
1.5 yrs

Alain Merieux

TITLE
Founding Chairman
AGE
80
TENURE
1.8 yrs

Jean-Luc Bélingard

TITLE
Non-Independent Director
COMPENSATION
€41K
AGE
70
TENURE
12.8 yrs

Harold Y. Boël

TITLE
Independent Director
COMPENSATION
€55K
AGE
54
TENURE
7.1 yrs

Fanny Letier

TITLE
Independent Director
COMPENSATION
€36K
AGE
39
TENURE
2.1 yrs

Philippe Archinard

TITLE
Non-Independent Director
COMPENSATION
€55K
AGE
59
TENURE
9 yrs

Marie-Hélène Habert-Dassault

TITLE
Independent Director
COMPENSATION
€36K
AGE
53
TENURE
7.1 yrs

Agnès Lemarchand

TITLE
Independent Director
COMPENSATION
€46K
AGE
64
TENURE
5.1 yrs

Marie-Paule Kieny

TITLE
Independent Director
COMPENSATION
€30K
AGE
63
TENURE
1.8 yrs

Frédéric Besème

TITLE
Employee director
COMPENSATION
€13K
AGE
62
TENURE
1.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess bioMérieux's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
    5. bioMérieux has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

BIM News

Simply Wall St News

bioMérieux S.A.'s (EPA:BIM) Earnings Grew 7.8%, Did It Beat Long-Term Trend?

Check out our latest analysis for bioMérieux Did BIM's recent earnings growth beat the long-term trend and the industry? … However, this one-year growth rate has been lower than its average earnings growth rate over the past 5 years of 16%, indicating the rate at which BIM is growing has slowed down. … I suggest you continue to research bioMérieux to get a more holistic view of the stock by looking at: Future Outlook: What are well-informed industry analysts predicting for BIM’s future growth?

Simply Wall St - –

Is It Too Late To Buy bioMérieux S.A. (EPA:BIM) At Its May Price?

bioMérieux is trading at price-to-earnings (PE) ratio of 34.08x, this tells us the stock is overvalued compared to the FR market average ratio of 17.36x , and overvalued based on current earnings compared to the Medical Equipment industry average of 31.57x. … ENXTPA:BIM Price Estimation Relative to Market, May 28th 2019 We understand BIM seems to be overvalued based on its current earnings, compared to its industry peers. … So, when we include the growth factor in our analysis, bioMérieux appears overvalued , based on the fundamentals.

Simply Wall St - –

Why Investors Should Run Towards bioMérieux S.A. (EPA:BIM)

This is the best time to buy stocks like bioMérieux S.A. … Generally, large-cap stocks are well-resourced and well-established meaning that a bear market will cause it to rejig some short-term capital allocations, but stock market volatility is hardly detrimental to its financial health and business operations. … The intrinsic value infographic in our free research report helps visualize whether BIM is currently mispriced by the market.

Simply Wall St - –

Is bioMérieux S.A.'s (EPA:BIM) 13% ROE Better Than Average?

The formula for ROE is: Return on Equity = Net Profit ÷ Shareholders' Equity Or for bioMérieux: 13% = €257m ÷ €2.0b (Based on the trailing twelve months to December 2018.) Most readers would understand what net profit is, but it’s worth explaining the concept of shareholders’ equity. … Does bioMérieux Have A Good Return On Equity? … Companies that can achieve high returns on equity without too much debt are generally of good quality.

Simply Wall St - –

Is bioMérieux S.A. (EPA:BIM) Worth €70.75 Based On Its Intrinsic Value?

by estimating the company's future cash flows and discounting them to their present value. … I will use the Discounted Cash Flow (DCF) model. … If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model

Simply Wall St - –

bioMérieux S.A. (EPA:BIM): Immense Growth Potential?

(EPA:BIM) released its earnings in December 2018,. … analyst forecasts seem fairly subdued, … the higher past 5-year average growth rate of 16%

Simply Wall St - –

I Built A List Of Growing Companies And bioMérieux (EPA:BIM) Made The Cut

The market is a voting machine in the short term, but a weighing machine in the long term, so share price follows earnings per share (EPS) eventually. … One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. … You can take a look at the company's revenue and earnings growth trend, in the chart below.

Simply Wall St - –

Here’s What bioMérieux S.A.’s (EPA:BIM) Return On Capital Can Tell Us

In particular, we'll consider its Return On Capital Employed (ROCE), as that can give us insight into how profitably the company is able to employ capital in its business. … What is Return On Capital Employed (ROCE)? … ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business.

Simply Wall St - –

Do Institutions Own bioMérieux S.A. (EPA:BIM) Shares?

Generally speaking, as a company grows, institutions will increase their ownership. … We also tend to see lower insider ownership in companies that were previously publicly owned. … Taking a look at our data on the ownership groups (below), it's seems that.

Simply Wall St - –

How Do Analysts See bioMérieux S.A. (EPA:BIM) Performing Over The Next Few Years?

In December 2018, bioMérieux S.A. … (EPA:BIM) released its latest earnings announcement, whicha … signalled

Simply Wall St - –

BIM Company Info

Description

bioMérieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company offers microbiology technology that involves culturing biological samples; and immunoassays technology based on antigen-antibody reaction, detects and measures infectious agents, such as bacteria, viruses, and parasites, as well as measures the specific biomarkers of various pathologies, such as metabolic, hormonal, infectious, etc. It also provides molecular biology for the detection of genetic sequences of deoxyribonucleic acid or ribonucleic acid; and companion diagnostic test based on biomarkers, as well as services for clinical and industrial laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is based in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Details
Name: bioMérieux S.A.
BIM
Exchange: ENXTPA
Founded: 1963
€9,029,585,463
117,802,811
Website: http://www.biomerieux.com
Address: bioMérieux S.A.
376 Chemin De l’Orme,
Marcy l'Etoile,
Rhône-Alpes, 69280,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA BIM Ordinary Shares Euronext Paris FR EUR 07. Jul 2004
OTCPK BMXM.F Ordinary Shares Pink Sheets LLC US USD 07. Jul 2004
DB EYWN Ordinary Shares Deutsche Boerse AG DE EUR 07. Jul 2004
LSE 0RUG Ordinary Shares London Stock Exchange GB EUR 07. Jul 2004
BATS-CHIXE BIMP Ordinary Shares BATS 'Chi-X Europe' GB EUR 07. Jul 2004
Number of employees
Current staff
Staff numbers
11,200
bioMérieux employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/17 20:33
End of day share price update: 2019/06/17 00:00
Last estimates confirmation: 2019/06/06
Last earnings filing: 2019/03/15
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Related Companies

© 2019 Simply Wall Street Pty Ltd, Community Design 2845206, US Design Patent #29/544/281, European Design Registration #2845206, Standard & Poor’s Financial Services LLC. All rights reserved.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2019, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2019)